Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
According to a case report by Otto ND and colleagues, intravenous glutathione therapy resulted in both subjective and objective symptom improvement for a patient with Parkinsons disease who was being conventionally treated
Certified Compliance: WHO-GMP, cGMP, ISO, HACCP, and FSSAI certified, USFDA guideline-maintained production process
Four molecule families have peer-reviewed clinical evidence supporting their use in microinfusion-style delivery: copper tripeptide GHK-Cu (collagen synthesis, gene-expression modulation), recombinant epidermal growth factor or sh-Oligopeptide-1 (keratinocyte proliferation, dermal restructuring), polydeoxyribonucleotide PDRN (adenosine A2A receptor activation, fibroblast stimulation, anti-melanogenesis), and a multi-molecular-weight hyaluronic acid system (50 kDa to 2000 kDa fractions, each with different penetration depth and biological role)
Product intended for research purposes only
US$ 24.76
US$ 20.30
US$ 26.16
US$ 22.14
US$ 25.92
US$ 24.23
